Infection with the pathogen Clostridium difficile is a significant source of healthcare-associated infections and estimated to account for 12 percent of all HAIs in the U.S.1 C. diff infection is the ...

A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests. Accurate diagnosis of CDI is critical for ...

Current hospital tests for the bacterium Clostridium difficile (C. difficile) are not accurate enough and a new two-stage process should be introduced to avoid misdiagnosis and its consequences. These ...

EPA also released regulatory guidance for test criteria and pesticide claims for these products, specifically “Methods and Guidance for Testing the Efficacy of Antimicrobial Products Against Spores of ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Cdiff Test to detect Clostridium difficile (C. difficile) ...

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile, a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in the United ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

SALT LAKE CITY--(BUSINESS WIRE)-- Great Basin Corporation, a privately held life sciences company developing novel, sample-to-result molecular diagnostic solutions, today announced the initiation of ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

A single Clostridium difficile infection presents an array of challenges for hospitals. A December 2015 study in the American Journal of Infection Control found C. difficile infections can increase ...

FDA Approves Orphan Drug Fidaxomicin for Pediatric CDI The FDA has granted orphan drug designation for all formulations of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in ...

On September 29, 2017, the U.S. Environmental Protection Agency (EPA) announced the availability of two final test method Standard Operating Procedures (SOP) for evaluating the efficacy of ...